Store

BioSurf RTU disinfection

SKU 60132
$91.00
In stock
1
Product Details

UPDATE: As of 6/4/20 heading into our warehouse. Expected by 6/8/20


High level grade of disinfection. BioSurf RTU cleans surfaces, implements, counter tops and more. Only 50 second contact time. Hospital grade, recognized by EPA, FDA, CDC.


To our valued professionals, CONCERNING CORONAVIRUS

The WHO today has officially declared the Coronavirus COVID-19 a global pandemic. As a result, many professionals have become concerned about disinfectant product efficacy.

The official term used by disinfectant regulators is “emerging pathogen” From Health Canada:

with a broad spectrum virucide, supported by an efficacy claim against any of: Adenovirus type 5, Bovine Parovirus, Canine Parvovirus, Poliovirus type 1 Reference: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-

products/applications-submissions/guidance-documents/disinfectants/safety-efficacy- requirements-hard-surface-disinfectant-drugs.html#b5

Concerning the enveloped emerging viral pathogen Coronavirus “COVID-19”
From the US EPA: “A product should be approved by EPA to inactivate at least one large or one small non-enveloped virus to be eligible for use against an enveloped emerging viral pathogen.” These include: (1) Picornaviridae, (2) Parvoviridae, (3) Caliciviridae, (4) Astroviridae, and (5) Polyomaviridae Reference:https://www.epa.gov/sites/production/files/2016- 09/documents/emerging_viral_pathogen_program_guidance_final_8_19_16_001_0.pdf

The most difficult of these benchmarks is Canine parvovirus.
BioSURF has the fastest recorded inactivation time worldwide with a 50 second claim. BioTEXT has the second fastest claim at 300 seconds.

Current Information: COVID-19 virus is believed to stay viable on surfaces for 9 days. The news media focus on Hand Sanitizing is important, but surfaces matter just as much.

Yours sincerely,

Dean Swift Chairman

page1image21405376

Health Canada will permit manufacturers to provide communications to the public

page1image21413248

regarding the expected efficacy of certain market authorized disinfectant drugs against

page1image21400768

the emerging pathogen

page1image21399424page1image21404992page1image21402496page1image21400576page1image21399040page1image27724848


Save this product for later